BOSTON — An early study of the combination of lorcaserin (Belviq) and phentermine showed no major differences in its primary endpoint of serotonergic adverse effects, and hinted at greater weight loss, researchers reported here.

In a phase II study, patients lost a greater proportion of their body weight over 12 weeks when adding twice-daily phentermine to their lorcaserin prescription, compared with lorcaserin alone (8.7% versus 3.8%), according to Steven Smith, MD, of Florida Hospital in Orlando, and colleagues.

But reductions in blood pressure and pulse rate were not as great for those who added phentermine to their regimens — and the highest-dose phentermine group had an increase in heart rate — but a clinician who works for Eisai emphasized that the study was not powered to look at the weight loss or cardiovascular endpoints.

READ FULL ARTICLE Curated publisher From Medical Page Today